Nevertheless, the small proportion of patients with meaningful clinical benefit might be masked among a larger proportion of patients who fail to benefit from Plk1 inhibition since no meaningful biomarkers were taken into account in most early phase clinical trials involving NSCLC [11]. The gene discussed is PLK1; the disease is non-small cell lung carcinoma.